TABLE 1.
Treatments for patients from whom samples were obtained and prevalence of Q151M and T69S-SS mutations
| Group and treatmenta | No. of available samples | No. of samples from which virus was amplified | No. of samples containing virus with the following mutation:
|
|
|---|---|---|---|---|
| Q151M | T69S-SS | |||
| Study group | ||||
| ZDV-ddI | 81 | 57 | 0 | 0 |
| ZDV-ddC | 71 | 39 | 1 | 1 |
| ZDV-ddC-SQV | 11 | 11 | 0 | 0 |
| ZDV/ZDV-d4T | 11 | 11 | 1 | 0 |
| ZDV/ZDV-ddI | 36 | 33 | 2 | 0 |
| ZDV/ZDV-ddC | 25 | 20 | 0 | 0 |
| ZDV/ddI | 125 | 110 | 0 | 0 |
| ZDV/ddC | 6 | 4 | 0 | 0 |
| Other | 74 | 60 | 2 | 1 |
| Total study samples | 440 | 363 | 6 | 2 |
| Control group | ||||
| ZDV | 169 | 145 | 0 | 0 |
| ddI | 19 | 15 | 0 | 0 |
| Drug naive | 127 | 114 | 0 | 0 |
| Total control samples | 315 | 274 | 0 | 0 |
a
ZDV, zidovudine; ddI, didanosine; ddC, zalcitabine; SQV, saquinavir; d4T, stavudine. Slashes denote successive treatments.